Leids Universitair Medisch Centrum

Running trials

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Source

• Recruiting

  NO Re-excision MelanomA - NORMA 2

  NCT07530887· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Source

• Recruiting

  Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer

  NCT05180864· Source

• Recruiting

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  NCT06172478· Phase 2· Source

• Enrolling by invitation

  Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

  NCT06066580· Phase 2· Source

• Active, not recruiting

  The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

  NCT05704205· Source

• Recruiting

  High-Risk prostatE Cancer radiatiOn Versus surgERy

  NCT05931419· Source

• Recruiting

  Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

  NCT05393791· Phase 2· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Active, not recruiting

  A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

  NCT05152147· Phase 3· Source

• Active, not recruiting

  A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

  NCT05060016· Phase 2· Source

• Active, not recruiting

  Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas

  NCT04425967· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Source

• Recruiting

  DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

  NCT07717437· Source

• Active, not recruiting

  Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT04663347· Phase 1/2· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

  NCT04449874· Phase 1· Source

• Recruiting

  A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

  NCT05999994· Phase 2· Source

• Active, not recruiting

  Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

  NCT03764553· Phase 2· Source

• Active, not recruiting

  Multicentric Randomised Trial for Resectable Gastric Cancer

  NCT02931890· Phase 2· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Source

• Active, not recruiting

  A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

  NCT02246621· Phase 3· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer3 recruiting
• Childhood cancers2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Lung cancer2 recruiting
• Melanoma2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Depression1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  The Pharmacological Effects of Using Cabozantinib With a Light Breakfast

  NCT05263245· Phase 2· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· Source

• Completed

  Reduced Anticoagulation Targets in ECLS (RATE)

  NCT04536272· Phase 3· Source

• Completed

  CIRSE Emprint Microwave Ablation Registry

  NCT03775980· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Source

• Completed

  Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

  NCT03173560· Phase 2· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source